Alessandra Alves Thole

Alessandra Alves Thole

Auto-generated profile, based on publicly available information

Alessandra Alves Thole

Department of Histology and Embryology, State University of Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Cranio-Maxillofacial Surgery
Verified
Journal Article
Closed access
JCJoão Vitor dos Santos Canellas
João Vitor dos Santos Canellas
RCRafael Cabral da Costa
Rafael Cabral da Costa
RBRicardo Caldeira Breves
Ricardo Caldeira Breves
GOGenilza Pereira de Oliveira
Genilza Pereira de Oliveira
CFCarlos Marcelo da Silva Figueredo
Carlos Marcelo da Silva Figueredo
FRFabio Gamboa Ritto
Fabio Gamboa Ritto

1 June 2020 in International Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
JCJoão Vitor dos Santos Canellas
João Vitor dos Santos Canellas
FRF.G. Ritto
F.G. Ritto
CFC.M.D.S. Figueredo
C.M.D.S. Figueredo
RFR.G. Fischer
R.G. Fischer
GOG.P. de Oliveira
G.P. de Oliveira
PMP.J.D. Medeiros
P.J.D. Medeiros

29 October 2019 in Cells
Verified
Journal Article
Open access
PDF file
DPDaphne Pinheiro
Daphne Pinheiro
IDIsabelle dos Santos Xavier Dias
Isabelle dos Santos Xavier Dias
KSKarina Ribeiro Silva
Karina Ribeiro Silva
ASAna Carolina Stumbo
Ana Carolina Stumbo
ATAlessandra Thole
Alessandra Thole
SCSimone Carvalho
Simone Carvalho
Fibrosis is a common feature in most pathogenetic processes in the liver, and usually results from a chronic insult that depletes the regenerative capacity of hepatocytes and activates multiple inflammatory pathways, recruiting resident and circulating immune cells, endothelial cells, non-parenchymal hepatic stellate cells, and fibroblasts, which become activated and lead to excessive extracellular matrix accumulation. The ongoing development of liver fibrosis results in a clinically silent and progressive loss of hepatocyte function, demanding the constant need for liver transplantation in clinical practice, and motivating the search for other treatments as the chances of obtaining compatible viable livers become scarcer. Although initially cell therapy has emerged as a plausible alternative to organ transplantation, many factors still challenge the establishment of this technique as a main or even additional therapeutic tool. Herein, the authors discuss the most recent advances and point out the corners and some controversies over several protocols and models that have shown promising results as potential candidates for cell therapy for liver fibrosis, presenting the respective mechanisms proposed for liver regeneration in each case.

1 January 2014 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
FNFabiana A. Neves
Fabiana A. Neves
ECErika Cortez
Erika Cortez
ABAmélia F. Bernardo
Amélia F. Bernardo
AMAna B.M. Mattos
Ana B.M. Mattos
AVAnatalia K. Vieira
Anatalia K. Vieira
AMAnibal S. Moura
Anibal S. Moura

6 May 2023 in Cancer Drug Resistance
Verified
Journal Article
Open access
PDF file
MRMateus de Almeida Rainho
Mateus de Almeida Rainho
.S.Priscyanne Barreto Siqueira
.Priscyanne Barreto Siqueira
IAIsis Amorim
Isis Amorim
AMAndre Luiz Mencalha
Andre Luiz Mencalha
ATAlessandra Alves Thole
Alessandra Alves Thole
Colorectal cancer (CRC) is the third most diagnosed cancer and the second most deadly type of cancer worldwide. In late diagnosis, CRC can resist therapy regimens in which cancer stem cells (CSCs) are intimately related. CSCs are a subpopulation of tumor cells responsible for tumor initiation and maintenance, metastasis, and resistance to conventional treatments. In this scenario, colorectal cancer stem cells (CCSCs) are considered an important key for therapeutic failure and resistance. In its turn, mitochondria is an organelle involved in many mechanisms in cancer, including chemoresistance of cytotoxic drugs due to alterations in mitochondrial metabolism, apoptosis, dynamics, and mitophagy. Therefore, it is crucial to understand the mitochondrial role in CCSCs regarding CRC drug resistance. It has been shown that enhanced anti-apoptotic protein expression, mitophagy rate, and addiction to oxidative phosphorylation are the major strategies developed by CCSCs to avoid drug insults. Thus, new mitochondria-targeted drug approaches must be explored to mitigate CRC chemoresistance via the ablation of CCSCs.

3 April 2017 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
RLRafaelle Lira
Rafaelle Lira
MOMariana Oliveira
Mariana Oliveira
MMMarcela Martins
Marcela Martins
CSCaroline Silva
Caroline Silva
SCSimone Carvalho
Simone Carvalho
LCLaís de Carvalho
Laís de Carvalho